FDA Sticks To Guns In Final Guidance On Production Changes

Law360, New York (March 4, 2014, 8:17 PM EST) -- The U.S. Food and Drug Administration on Tuesday finalized guidance describing the types of low-risk drug manufacturing changes that only need to be reported annually, backing away from a few proposals that companies deemed burdensome but declining for now to consolidate scattered policies on the subject.

In its guidance, the FDA discussed post-approval changes to a drug that are unlikely to affect product safety or effectiveness and therefore can be disclosed on a yearly basis. By contrast, more dramatic changes can require advance authorization from the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.